Data collected on infectious diseases, which disproportionally affect low- and middle-income countries, are often fragmented, of sub-optimal quality and use very heterogeneous methods to assess and/or analyse similar conditions. Many of the research studies include small numbers of patients, and reports or publications are often delayed or not made available, such that the data are lost to any further analysis. These deficiencies are especially acute in the context of emerging infections where initial data must be collected in the midst of a rapidly evolving situation, and in neglected tropical infections where patients are often geographically disparate. All of these factors contribute to production of extremely heterogeneous, dispersed data sets with few opportunities for valid comparison.
By pooling data into harmonised platforms that integrate clinical outcomes with pharmacological and molecular information, we can circumvent many of these challenges. Analysis of larger pooled data sets increases the power to determine optimal treatments, provide evidence on the most effective outbreak responses, and can reveal differences in drug efficacy and safety over time and in specific vulnerable populations (e.g. infants, pregnant women, and patients with co-morbidities such as HIV, malnutrition, or genomic disorders), which cannot be discerned from smaller individual studies.
IDDO has established accessible and trusted data platforms for malaria and Ebola. These platforms enable inter- and cross-discipline analysis of global data on these diseases. As a part of the platform, long-term security and accessibility of data are ensured in order to maximise utility by the health, research and humanitarian communities.
IDDO is working closely with the research community, ISARIC, the WHO's GOARN, and policy makers to respond to the unprecedented threat caused by the outbreak. IDDO's focus is the dissemination of standards and best practice to ensure the optimal collection of data. The aim is to address knowledge gaps and improve treatment outcomes for people affected by COVID-19.
Substandard and falsified (SF) medicines negate the multiple benefits of modern healthcare, so good quality medical products are essential. By sharing global expertise and collating information, IDDO’s Medicine Quality Research Group strengthens knowledge of the scale of the problem and raises vital awareness among key stakeholders.
Antimicrobial resistance (AMR) is a serious threat to global public health that threatens the effective prevention and treatment of a range of infections caused by microorganisms such as bacteria, parasites, viruses and fungi. AMR can result in treatment failure, prolonged illness and increased healthcare costs.
Chagas disease, also known as American Trypanosomiasis, is a neglected disease caused by the Trypanosoma cruzi parasite. It is endemic in Latin America with increased migration contributing to rising patient numbers in non-endemic countries. Chagas disease has a high burden of morbidity and mortality affecting ~6-7 million people worldwide.
IDDO is currently scoping several new disease themes. As part of this process, IDDO conducts a scoping and feasibility assessment to gain an understanding of the clinical data landscape for that disease and whether a data platform would be of value to help advance research and answer critical questions.